Yuhan Zhu1, Yanyan Liu2, Jing Zhao1, Qingqing Han1, Lei Liu1, Xiaoxu Shen3. 1. Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine, No. 11, Bei San Huan Dong Lu, Chaoyang District, Beijing, 100029, China. 2. YEDA Hospital, Yantai, China. 3. Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine, No. 11, Bei San Huan Dong Lu, Chaoyang District, Beijing, 100029, China. alienstg@163.com.
Abstract
OBJECTIVE: This meta-analysis was performed to evaluate the efficacy and safety of monoclonal antibodies against calcitonin gene-related peptide (CGRP) for episodic migraine prevention. METHODS: MEDLINE, EMBASE, Web of Science, and the Cochrane Library were searched from inception to April 2018. Studies considered to be eligible were randomized controlled trials about efficacy and safety of calcitonin gene-related peptide monoclonal antibody for episodic migraine prevention. RESULTS: Eight randomized controlled trials involving 2292 patients were included. The outcomes of this meta-analysis presented that CGRP monoclonal antibodies for preventive treatment of episodic migraine significantly reduced the monthly migraine days from baseline [weighted mean difference (WMD) = - 1.52; 95%CI, - 1.92 to - 1.11; Z = 7.40; P < 0.001] and monthly acute migraine-specific medication consumption from baseline [WMD = - 1.45; 95%CI, - 2.17 to - 0.72; Z = 3.93; P < 0.001], as compared with placebo group. CGRP monoclonal antibodies for preventive treatment of episodic migraine significantly increased the ≥ 50% reduction from baseline in migraine days per month [RR = 1.54; 95%CI, 1.38 to1.71; Z = 7.88; P < 0.001]. The adverse events were similar between the CGRP monoclonal antibody group and placebo group (P = 0.998). The outcomes of subgroup analysis showed that erenumab, galcanezumab, and fremanezumab significantly reduced the monthly migraine days from baseline and increased the ≥ 50% reduction from baseline in migraine days per month. Both erenumab and fremanezumab significantly reduced from baseline. CONCLUSIONS: Based on the results of this meta-analysis, CGRP monoclonal antibodies significantly reduced the monthly migraine days and acute migraine-specific medication. CGRP monoclonal antibodies were effective and safe for preventive treatment of episodic migraine.
OBJECTIVE: This meta-analysis was performed to evaluate the efficacy and safety of monoclonal antibodies against calcitonin gene-related peptide (CGRP) for episodic migraine prevention. METHODS: MEDLINE, EMBASE, Web of Science, and the Cochrane Library were searched from inception to April 2018. Studies considered to be eligible were randomized controlled trials about efficacy and safety of calcitonin gene-related peptide monoclonal antibody for episodic migraine prevention. RESULTS: Eight randomized controlled trials involving 2292 patients were included. The outcomes of this meta-analysis presented that CGRP monoclonal antibodies for preventive treatment of episodic migraine significantly reduced the monthly migraine days from baseline [weighted mean difference (WMD) = - 1.52; 95%CI, - 1.92 to - 1.11; Z = 7.40; P < 0.001] and monthly acute migraine-specific medication consumption from baseline [WMD = - 1.45; 95%CI, - 2.17 to - 0.72; Z = 3.93; P < 0.001], as compared with placebo group. CGRP monoclonal antibodies for preventive treatment of episodic migraine significantly increased the ≥ 50% reduction from baseline in migraine days per month [RR = 1.54; 95%CI, 1.38 to1.71; Z = 7.88; P < 0.001]. The adverse events were similar between the CGRP monoclonal antibody group and placebo group (P = 0.998). The outcomes of subgroup analysis showed that erenumab, galcanezumab, and fremanezumab significantly reduced the monthly migraine days from baseline and increased the ≥ 50% reduction from baseline in migraine days per month. Both erenumab and fremanezumab significantly reduced from baseline. CONCLUSIONS: Based on the results of this meta-analysis, CGRP monoclonal antibodies significantly reduced the monthly migraine days and acute migraine-specific medication. CGRP monoclonal antibodies were effective and safe for preventive treatment of episodic migraine.
Authors: David W Dodick; Peter J Goadsby; Egilius L H Spierings; Joel C Scherer; Steven P Sweeney; David S Grayzel Journal: Lancet Neurol Date: 2014-08-10 Impact factor: 44.182
Authors: Peter J Goadsby; Uwe Reuter; Yngve Hallström; Gregor Broessner; Jo H Bonner; Feng Zhang; Sandhya Sapra; Hernan Picard; Daniel D Mikol; Robert A Lenz Journal: N Engl J Med Date: 2017-11-30 Impact factor: 91.245
Authors: Stewart Tepper; Messoud Ashina; Uwe Reuter; Jan L Brandes; David Doležil; Stephen Silberstein; Paul Winner; Dean Leonardi; Daniel Mikol; Robert Lenz Journal: Lancet Neurol Date: 2017-04-28 Impact factor: 44.182
Authors: Joshua M Cohen; David W Dodick; Ronghua Yang; Lawrence C Newman; Thomas Li; Ernesto Aycardi; Marcelo E Bigal Journal: Headache Date: 2017-09-01 Impact factor: 5.887
Authors: Kasper Adelborg; Szimonetta Komjáthiné Szépligeti; Louise Holland-Bill; Vera Ehrenstein; Erzsébet Horváth-Puhó; Victor W Henderson; Henrik Toft Sørensen Journal: BMJ Date: 2018-01-31
Authors: Messoud Ashina; Joel Saper; Roger Cady; Barbara A Schaeffler; David M Biondi; Joe Hirman; Susan Pederson; Brent Allan; Jeff Smith Journal: Cephalalgia Date: 2020-02-19 Impact factor: 6.292
Authors: Robert Belvís; Pablo Irimia; Patricia Pozo-Rosich; Carmen González-Oria; Antonio Cano; Javier Viguera; Belén Sánchez; Francisco Molina; Isabel Beltrán; Agustín Oterino; Elisa Cuadrado; Angel Gómez-Camello; Miguel Alberte-Woodward; Carmen Jurado; Teresa Oms; David Ezpeleta; Javier Díaz de Terán; Noemí Morollón; Germán Latorre; Marta Torres-Ferrús; Alicia Alpuente; Raquel Lamas; Carlos Toledano; Rogelio Leira; Sonia Santos; Margarita Sánchez Del Río Journal: J Headache Pain Date: 2021-07-17 Impact factor: 7.277